Clinical Trial Update: Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab in combination with 8 Gy single-fraction radiotherapy for advanced oligoprogressive non-small cell lung cancer has been te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Oncology Institute of Southern Switzerland | Conditions: NSCLC Stage IV | Phase 2 | Status: TERMINATED